Tscm Expander® is a mixing of cytokines (IL-7, IL-15, etc.) at a certain proportion. It specifically expands the T-memory stem cells and significantly extends the in vivo post-infusion survival time of T cells with specific killing ability, thus remarkably improving the efficacy of immune cell therapy against the tumor. In the traditional cell expansion procedures, after the monocytes activated by CD3/CD28 monoclonal antibodies are further expanded by IL-2, the majority of T cells highly differentiate to effector/memory T cells. These cells are weak in self-renewal ability with short post-infusion survival time in vivo, resulting in poor therapeutic effects. Tscm Expander® takes the place of IL-2 in the expansion of activated T cells so that 30% of the expanded T cells are transformed into T-memory stem cells. This greatly prolongs the post-transplant survival time of immune cells in vivo and improves the therapeutic effect. The T memory stem cell expanders of Tscm Expander® are produced with raw materials of pharmaceutical applicable level. The host protein residue, nucleic acid residue and common pathogens are strictly controlled, and the production and quality management procedures of the product comply with GMP regulations to ensure the traceability of the production process and all raw materials.
